Mark J. Gergen - 02 Jan 2025 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role
Executive Chairman, Director
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Jan 2025
Net transactions value
-$223,805
Form type
4
Filing time
03 Jan 2025, 20:24:17 UTC
Previous filing
11 Dec 2024
Next filing
08 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Tax liability $223,805 -23,313 -3.6% $9.60 630,726 02 Jan 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 2, 2024.
F2 Includes 2,748 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on January 2, 2025.